Berg Diagnostics Launches Molecular Diagnostics Services and Products at American Association for Cancer Research (AACR) 102nd Annual Meeting

ORLANDO, Florida,, April 4, 2011 - Berg Diagnostics, a member of the Berg Pharma, Inc group of companies
with Berg Biosystems and Cytotech Labs, is a Boston-based molecular
diagnostics company that officially launched its molecular diagnostics
services and products at AACR meeting from April 2nd - 6th in Orlando,
Florida.

(Logo: photos.prnewswire.com/prnh/20110404/CL76832LOGO )

The company offers enabling technologies such as high-throughput
omics-based molecular profiling, biomarker validation, and regulated
bioanalysis, facilitating its client base to decipher differential molecular
signatures between normal and disease states, reveal underlying
pathophysiology, identify and validate novel biomarkers. In addition, it has
its proprietary proteomic, lipidomic, and metabolomic platforms that allow
for an integrative data-driven approach to diagnostics.

Dr. Renu Virmani, LTC, MC (US Army), President and Medical Director of CV
Path in Gaithlesnburg, MD, Clinical Professor of Pathology at Georgetown
University, and former Chair, Division of Cardiovascular Pathology, Armed
Forces Institute of Pathology commented, "These Technologies will likely
discover new biomarkers, which should help treat patients get individualized
medicine."

"We are very excited to showcase our research capabilities and product
offerings to cancer researchers worldwide," explained Shen Luan, President
and CTO of Berg Diagnostics. "The successful delivery of molecular
diagnostics is the foundation of personalized medicine. Berg Diagnostics is
well-positioned to translate the promise of personalized medicine into
palpable human impact."

In addition, a product portfolio of over 100 research-based ELISA kits
would be unveiled at Booth # 177. The list of ELISA kits covers research
categories such as angiogenesis, apoptosis, endocrinology, immunology,
inflammation, oncology, and signal transduction. Complete product catalogs
are found on the new Berg Diagnostics website.

"Shen has been able to combine the latest cutting edge 'omic' platforms
to enable biological mining to the deepest layers of understanding. The
company is poised to be an industry leader in actually separating signal from
noise in analyzing biological samples which will be the foundation of truly
enabling personalized medicine," noted Niven R. Narain, President and CTO of
Berg Biosystems, and Co-founder of Berg Diagnostics.

About Berg Diagnostics LLC

Berg Diagnostics is a Boston-based molecular diagnostics company that
offers high-throughput omics-based molecular profiling, biomarker validation,
and regulated bioanalysis to accelerate development of molecular therapeutics
and diagnostics. Armed with the state-of-the-art instrumentation platforms,
the company serves to catalyze project end-points in therapeutic and
biomarker development.

Ashley Potts, +1-617-939-1071